2-(4-methanesulfonylphenyl)-5-({1-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-4-yl}methoxy)pyridine

• ChemBase ID: 72863
• Molecular Formular: C23H28N4O4S
• Molecular Mass: 456.55782
• Monoisotopic Mass: 456.1831264
• SMILES: c1(ccc(cn1)OCC1CCN(CC1)c1onc(n1)C(C)C)c1ccc(cc1)S(=O)(=O)C
• Canonical SMILES: CC(c1noc(n1)N1CCC(CC1)COc1ccc(nc1)c1ccc(cc1)S(=O)(=O)C)C
• InChI: InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3
• InChIKey: AYJRTVVIBJSSKN-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-(4-methanesulfonylphenyl)-5-({1-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-4-yl}methoxy)pyridine
• IUPAC Traditional name: 5-{[1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]methoxy}-2-(4-methanesulfonylphenyl)pyridine
• Synonyms: GSK1292263

Database IDs

• CAS Number: 1032823-75-8
• PubChem SID: 162037784
• PubChem CID: 24996872

CALCULATED PROPERTIES

• Acid pKa: 19.687912
• H Acceptors: 7
• H Donor: 0
• LogD (pH = 5.5): 4.1019306
• LogD (pH = 7.4): 4.108558
• Log P: 4.108643
• Molar Refractivity: 123.8149 cm^3
• Polarizability: 48.64227 Å^3
• Polar Surface Area: 98.42 Å^2
• Rotatable Bonds: 7
• Lipinski's Rule of Five: true

PROPERTIES

Safety Information

• Storage Condition: -20°C

Pharmacology Properties

• Target: GPR

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S2149

Research Area

• Description: Hyperlipidaemia ,Type-2 diabetes mellitus

Biological Activity

• Description: GSK-1292263 is a novel GPR119 agonist.
• Targets: GPR119
• In Vitro: GSK-1292263 is selected from 1538 compounds by using Hypo1, the Fit-Value and Estimate of GSK-1292263 that is aligned in Hypo1 are 8.8 and 7.7 (nM), respectively. ^[1]
• In Vivo: GSK-1292263 administrated at a single dose of 3-30 mg/kg in the absence of nutrients correlates with increased levels of circulating gastrointestinal peptides, including glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), peptide YY (PYY) and glucagon in male Sprague-Dawley rats, the increase is enhanced following administration of glucose in the oral glucose tolerance test (OGTT). GSK-129226 significant increases in the peak insulin response and insulin AUC(0-15 min) of 30-60% compared with values in the vehicle control cohort in the intravenous glucose tolerance test in rats, this insulin upregulation correlated with a significant increase in the glucose disposal rate. GSK-1292263 is associated with a statistically significant increase in insulin immunoreactivity in pancreatic sections in a 6-week study performed in Zucker diabetic fatty rats, compared with insulin immunoreactivity in samples obtained from rats receiving vehicle control. GSK-1292263 administrated at dose of 10 or 30 mg/kg or vehicle control at 2 hours prior to insulin infusion in hyperinsulinemic-euglycemic clamps stimulates glucagon secretion without increasing blood glucose levels Sprague-Dawley rats. ^[2]
• Clinical Trials: GSK1292263 has finished Phase II clinical trial for Diabetes Mellitus, Type 2.

Protocol

• Protocol: Animal Study ^[2]
• Animal Models: male Sprague-Dawley rats
• Formulation: 0.9% sodium chloride solution
• Doses: 3-30 mg/kg

References

• References: [1] Zhu X, et al. Eur J Med Chem, 2011, 46(7), 2901-2907.
• References: [2] Brown KK, et al. Diabetes, 2010, 59(Suppl. 1), Abst 1733-P.

REFERENCES

• Zhu X, et al. Eur J Med Chem, 2011, 46(7), 2901-2907.
• Brown KK, et al. Diabetes, 2010, 59(Suppl. 1), Abst 1733-P.